Submit an e-Poster

• Delegates are invited to submit their poster for exhibition at NTW’25 by 14st April 2025.
• There are no fees to submit.
• Posters must be submitted via this link: https://tuk-edu.vfairs.com/backend/v2/abstract/register
• Posters sent by post will not be accepted. No exceptions will be made.

General Guidelines

• The poster must address questions or an identified issue, detail clinical observations, or contain primary scientific data.
• The poster should be submitted in clear English. Only posters submitted in English can be accepted.
• All research studies submitted that involve human subjects or experimental animals must comply with the Declaration of Helsinki.

Important Dates

• 14th April 2025:
  • Poster submission deadline

• 28th April 2025:
  • You will be informed by this date as to whether your poster has been accepted for exhibition at NTW’25.

• 6th May 2025:
  • Accepted posters will be accessible and able to be viewed by all registered attendees at NTW’25 conference.

Main Topics

• Coagulation & Natural Anticoagulants
• Fibrinolysis and Proteolysis
• Haemostatic Systems in Cancer, Inflammation and Immunity Immunothrombosis
• Pediatrics
• Patient centred care delivery
• Platelets and Megakaryocytes
• Psychological impact of thrombosis
• Service improvement projects
• Thrombosis and psychiatric care
• Venous Thromboembolism
• Women and thrombosis

The topic of your work must be selected during the submission process.

Preparing your e-Poster, guidance
All ePosters will be available on-demand on the NTW’25 virtual conference platform.

Authors and Co-Authors

• The first/presenting author is responsible for ensuring that all authors have read the poster and agreed to be co-authors.
• The presenting author must register to attend for NTW’25 virtual conference.
• The Poster will be withdrawn if registration is not completed by 1 May 2025.

Conflict of Interest

• It is the intent of Thrombosis UK to provide high-quality sessions focused on educational content that is free from commercial influence or b submitting/presenting author of a poster is required to declare any potential conflicts of interest for the presenting author during submission.

e-Poster Format:

• Your e-Poster should be formatted in a PDF as a landscape/horizontal slide that is 16:9 ratio, NOT 4:3. Presenting in 4:3 format may cause you distorted. (There is no file size limit)
• Place a heading that runs the full width of the e-Poster at the top in a large-sized type.
• The text should be no less than 8 mm (22 point font) and preferably larger.
• Use a constant font throughout the e-Poster.
• Use a black and bold type to ensure legibility and let your important points stand out.
• We suggest that you show the preferred sequence in which your e-Poster should be reviewed; this can be done by using 3 – 5 columns so the eye movement is down the columns.
• The figures tables should cover approximately 50% of the e-Poster area.
• Highlight your main findings. Don’t hide your conclusions, consider putting them at the top of the right column or alternatively start with the
• We suggest that you structure your e-Poster by Introduction, Methods, Results, and Conclusions. State your aims in the end of the introduction.

Other Recommendations and guidance:

• If possible, avoid abbreviations and acronyms, especially in the Conclusion section.
• Seek simplicity, keep text to a minimum and avoid redundancies.
• Title: Clearly indicate the nature of the investigation. The poster title and text may not contain trade names. The NTW’25 Committee reserves the right to replace trade names in accepted posters.
• Conclusion (or Conclusions):

Aims

• Methods: Should contain sufficient information to be able to understand the experimental design, the analytical techniques and the s study
• Results: Which should contain objective data to answer the scientific question(s). A maximum of two total tables or figures may be submitted. Please be sure to number each table and figure and cite each table and figure in the poster text.
• Conclusion (or Conclusions): Should only provide conclusions of the study directly supported by the results, along with implications for avoiding speculation and over-generalisation.

Other Items for Consideration

• In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognised medicl ethics committee.
• If the research included in your Poster was supported by a pharmaceutical or diagnostics company, you can indicate this when submitted.
• Please indicate the funding agency of your work if applicable.
• There is not a specific area to enter this information, it will need to be included as part of the poster text.
• Abbreviations should be defined.
• If off-label use of a drug was involved in the study, please state this clearly.

Poster Submission Instructions

• Do not password protect the file Only
• Submit a one-page PDF
• You will receive email confirmation when the e-poster has been successfully uploaded. If you do not receive confirmation within 24 hours, please contact:
  jo@thrombosisuk.org
• Any questions - please contact jo@thrombosisuk.org

After Submission

A panel of experts will review submitted posters. The presenting author will be contacted on their email address provided during submission.

The reviewers will judge according to the following criteria:

• Is the poster original?
• Does it address an important area in thrombosis?
• Does it address an important area in thrombosis?
• Is the poster clearly written with all salient facts?
• Does the work adhere to ethical guidelines?
• Is there evidence of statistical method if appropriate?
• Are the conclusions justified by the results?

Please note:

No revisions can be made after the poster deadline.

Withdrawal Policy

If authors wish to withdraw their posters from presentation or publication they are required to notify Thrombosis UK via e-mail to jo@thrombosisuk before Monday 6 May 2025.

Withdrawn posters will not be published.

All e-Posters will be available on-demand on the NTW’25 virtual conference platform.